Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study

[1]  D. van Soolingen,et al.  The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  P. V. van Helden,et al.  Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa , 2013, PloS one.

[3]  M. O’Donnell,et al.  Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  C. Kvasnovsky,et al.  Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection , 2013, Emerging infectious diseases.

[5]  Marisa Klopper,et al.  Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa , 2013, Emerging infectious diseases.

[6]  K. Dheda,et al.  What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa? , 2013, PloS one.

[7]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[8]  P. V. van Helden,et al.  Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[9]  P. V. van Helden,et al.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. , 2012, The Journal of antimicrobial chemotherapy.

[10]  P. V. van Helden,et al.  Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. , 2012, Microbial drug resistance.

[11]  A. Diacon,et al.  Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[12]  Giovanni B Migliori,et al.  The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? , 2012, The Lancet.

[13]  C. Rodrigues,et al.  Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  P. V. van Helden,et al.  Mycobacterium tuberculosis Population Structure Determines the Outcome of Genetics-Based Second-Line Drug Resistance Testing , 2012, Antimicrobial Agents and Chemotherapy.

[15]  G. Tyrrell,et al.  Canadian Multicenter Laboratory Study for Standardized Second-Line Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis , 2011, Journal of Clinical Microbiology.

[16]  C. Kvasnovsky,et al.  Extensively Drug-Resistant TB in Eastern Cape, South Africa: High Mortality in HIV-Negative and HIV-Positive Patients , 2011, Journal of acquired immune deficiency syndromes.

[17]  M. Murray,et al.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Kvasnovsky,et al.  Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study , 2010, The Lancet.

[19]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[20]  Parissa Farnia,et al.  Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. , 2009, Chest.

[21]  C. Horsburgh,et al.  Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  Evan W. Orenstein,et al.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.

[23]  Sonya S. Shin,et al.  Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study , 2008, The Lancet.

[24]  Sharon S. Choi,et al.  Comprehensive treatment of extensively drug-resistant tuberculosis. , 2008, The New England journal of medicine.

[25]  G. Migliori,et al.  First tuberculosis cases in Italy resistant to all tested drugs. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[26]  P. V. van Helden,et al.  Safe Mycobacterium tuberculosis DNA Extraction Method That Does Not Compromise Integrity , 2006, Journal of Clinical Microbiology.

[27]  H S F Fraser,et al.  Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  D van Soolingen,et al.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology , 1997, Journal of clinical microbiology.

[29]  R. Chaisson,et al.  Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection , 1997, AIDS.

[30]  V. Leimane,et al.  Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs , 2008 .

[31]  A. Laszlo,et al.  Anti-tuberculosis drug resistance in the world. Fourth global report. The WHO / IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2002-2007. , 2003 .